These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30469350)

  • 41. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.
    Hoofring SA; Lopez R; Hock MB; Kaliyaperumal A; Patel SK; Swanson SJ; Chirmule N; Starcevic M
    Bioanalysis; 2013 May; 5(9):1041-55. PubMed ID: 23641695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The potential of monoclonal antibodies for colorectal cancer therapy.
    Heidari F; Madadi S; Alizadeh N; Alimardani MH; Safari A; Armand MH; Pishgahzadeh E; Soleimani M
    Med Oncol; 2023 Aug; 40(9):273. PubMed ID: 37603117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials.
    Carrasco-Triguero M; Dere RC; Milojic-Blair M; Saad OM; Nazzal D; Hong K; Kaur S
    Bioanalysis; 2019 Sep; 11(17):1555-1568. PubMed ID: 31208199
    [No Abstract]   [Full Text] [Related]  

  • 45. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics.
    Martin KP; Grimaldi C; Grempler R; Hansel S; Kumar S
    MAbs; 2023; 15(1):2191301. PubMed ID: 36998195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies.
    Partridge MA; Purushothama S; Elango C; Lu Y
    J Immunol Res; 2016; 2016():6262383. PubMed ID: 27556048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.
    Lu Y; Khawli LA; Purushothama S; Theil FP; Partridge MA
    J Immunol Res; 2016; 2016():8141269. PubMed ID: 27642612
    [No Abstract]   [Full Text] [Related]  

  • 49. The safety and side effects of monoclonal antibodies.
    Hansel TT; Kropshofer H; Singer T; Mitchell JA; George AJ
    Nat Rev Drug Discov; 2010 Apr; 9(4):325-38. PubMed ID: 20305665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse Reactions to Biologic Therapy.
    Patel SV; Khan DA
    Immunol Allergy Clin North Am; 2017 May; 37(2):397-412. PubMed ID: 28366484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychosis as an adverse effect of monoclonal antibody immunotherapy.
    Essali N; Goldsmith DR; Carbone L; Miller BJ
    Brain Behav Immun; 2019 Oct; 81():646-649. PubMed ID: 31170448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.
    Cui Y; Cui P; Chen B; Li S; Guan H
    Drug Dev Ind Pharm; 2017 Apr; 43(4):519-530. PubMed ID: 28049357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk.
    Bivi N; Moore T; Rodgers G; Denning H; Shockley T; Swearingen CA; Gelfanova V; Calderon B; Peterson DA; Hodsdon ME; Siegel RW; Higgs RE; Konrad RJ
    MAbs; 2019 Jul; 11(5):861-869. PubMed ID: 31099718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review on modeling anti-antibody responses to monoclonal antibodies.
    Gómez-Mantilla JD; Trocóniz IF; Parra-Guillén Z; Garrido MJ
    J Pharmacokinet Pharmacodyn; 2014 Oct; 41(5):523-36. PubMed ID: 25027160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid.
    Yehuda S; Padler-Karavani V
    Front Immunol; 2020; 11():21. PubMed ID: 32038661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody.
    Clarke J; Leach W; Pippig S; Joshi A; Wu B; House R; Beyer J
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):219-26. PubMed ID: 15546677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pre-existing Antibody: Biotherapeutic Modality-Based Review.
    Gorovits B; Clements-Egan A; Birchler M; Liang M; Myler H; Peng K; Purushothama S; Rajadhyaksha M; Salazar-Fontana L; Sung C; Xue L
    AAPS J; 2016 Mar; 18(2):311-20. PubMed ID: 26821802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycosylation-dependent antitumor therapeutic monoclonal antibodies.
    Zhang Y; Fan C; Zhang L; Ma X
    Prog Mol Biol Transl Sci; 2019; 163():471-485. PubMed ID: 31030759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.